What is Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021?

Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 is Malaysia P.U. (A), cited as P.U. (A) 412 2021, currently marked in force and first recorded in 2021.

Is Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 still in force?

Yes — Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 is currently in force.

When did Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 take effect?

Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 was first recorded in 2021.

How many sections does Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 have?

Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 contains 2 sections.

Where can I read the official version of Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021?

The official text of Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 is published at lom.agc.gov.my.

P.U. (A)In force

Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021

The full official text, structured for quick navigation. Copy any provision or jump straight to a section.

Open source PDF Report an issue

Enacted: 2021
Sections: 2

Front matterCover and publication detailsOpen

P.U. (A) 412

WARTA KERAJAAN PERSEKUTUAN

FEDERAL GOVERNMENT

GAZETTE

PERINTAH RACUN (PINDAAN SENARAI RACUN)

(NO. 2) 2021

POISONS (AMENDMENT OF POISONS LIST)

(NO. 2) ORDER 2021

DISIARKAN OLEH/

JABATAN PEGUAM NEGARA/

ATTORNEY GENERAL’S CHAMBERS

P.U. (A) 412 2

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2021

Opening note

Preamble

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [Akta 366], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut: Nama

Seksyen 1

Perintah ini bolehlah dinamakan Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021.

Pindaan Jadual Pertama

Seksyen 2

Akta Racun 1952 dipinda dalam Jadual Pertama—

(a)

dalam Senarai Racun—

(i)

dengan memasukkan selepas butiran “Acebutolol; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Bahagian I

Part I

Bahagian II

Part II

Exempt

Group A

Group B

Group C

Group D

“Aceclofenac

All preparations”;

P.U. (A) 412 3

(ii)

dengan memotong butiran “Ambrisentan” dan butir-butir yang berhubungan dengannya;

(iii)

dengan memasukkan selepas butiran “Amantadine and other substances structurally derived therefrom; their salts unless specified elsewhere in the List” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ambrisentan

All preparations”;

(iv)

dengan memasukkan selepas butiran “Cilazapril” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Cilnidipine

All preparations”;

P.U. (A) 412 4

(v)

dengan memasukkan selepas butiran “Ectylurea” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Edaravone

All preparations”;

(vi)

dengan menggantikan butiran “Ethclorvynol” dengan butiran “Ethchlorvynol”;

(vii)

dengan menggantikan butiran “Glucose” dengan butiran “Glucose unless specified elsewhere in the List”;

(viii)

dalam senarai “Monoclonal antibody; includes the following:”—

(A)

dengan memasukkan selepas butiran “Brodalumab” butiran “Brolucizumab”;

(B)

dengan memasukkan selepas butiran “Rituximab” butiran “Romosozumab”; dan

(C)

dengan memasukkan selepas butiran “Secukinumab” butiran “Siltuximab”;

P.U. (A) 412 5

(ix)

dengan memasukkan selepas butiran “Ripasudil” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Risdiplam

All preparations”;

(x)

dengan memotong butiran “Siltuximab” dan butir-butir yang berhubungan dengannya;

(xi)

dengan memasukkan selepas butiran “Simvastatin” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Siponimod

All preparations”;

P.U. (A) 412 6

(xii)

dengan memasukkan selepas butiran “Succinylated gelatin” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Sucroferric oxyhydroxide

All preparations”;

(xiii)

dengan memasukkan selepas butiran “Terconazole” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Teriflunomide

All preparations”; dan

P.U. (A) 412 7

(xiv)

dengan memasukkan selepas butiran “Tipepidine hybenzate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Tipiracil

All preparations”; dan

(b)

dalam Lampiran kepada Senarai Racun—

(i)

dalam senarai “Analgesics including antipyretic and anti-inflammatory agents:”, dengan memasukkan sebelum butiran “Acetanilide; alkylacetanilides” butiran “Aceclofenac”;

(ii)

dalam senarai “Antihypertensives:”, dengan memasukkan selepas butiran “Cilazapril” butiran “Cilnidipine”;

(iii)

dalam senarai “Antineoplastic agents and Immunosuppressants:”—

(A)

dengan memasukkan selepas butiran “Rituximab” butiran “Romosozumab”;

(B)

dengan memasukkan selepas butiran “Simeprevir” butiran “Siponimod”; dan

(C)

dengan memasukkan selepas butiran “Temsirolimus” butiran “Teriflunomide”;

P.U. (A) 412 8

(iv)

dalam senarai “Hypnotics and sedatives:”, dengan menggantikan butiran “Ethclorvynol” dengan butiran

“Ethchlorvynol”; dan

(v)

dalam senarai “Miscellaneous:”—

(A)

dengan memasukkan selepas butiran “Brinzolamide” butiran “Brolucizumab”;

(B)

dengan memasukkan selepas butiran “Dutasteride” butiran “Edaravone”;

(C)

dengan menggantikan butiran “Glucose” dengan butiran “Glucose unless specified elsewhere in the List”;

(D)

dengan memasukkan selepas butiran “Ripasudil” butiran “Risdiplam”;

(E)

dengan memasukkan selepas butiran “Succinylated gelatin” butiran “Sucroferric oxyhydroxide”; dan

(F)

dengan memasukkan selepas butiran “Tiludronic acid; its salts” butiran “Tipiracil”.

Dibuat 15 Oktober 2021

[KKM.R.600-1/1/56; PN(PU2)172/XIX]

KHAIRY JAMALUDDIN ABU BAKAR

Menteri Kesihatan

P.U. (A) 412 9

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2021

Opening note

Preamble

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order: Citation 1. This order may be cited as the Poisons (Amendment of Poisons List) (No. 2) Order 2021. Amendment of First Schedule 2. The Poisons Act 1952 is amended in the First Schedule—

(a)

in the Poisons List—

(i)

by inserting after the item “Acebutolol; its salts” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Aceclofenac

All preparations”;

P.U. (A) 412 10

(ii)

by deleting the item “Ambrisentan” and the particulars relating to it;

(iii)

by inserting after the item “Amantadine and other substances structurally derived therefrom; their salts unless specified elsewhere in the List” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Ambrisentan

All preparations”;

(iv)

by inserting after the item “Cilazapril” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Cilnidipine

All preparations”;

(v)

by inserting after the item “Ectylurea” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Edaravone

All preparations”;

P.U. (A) 412 11

(vi)

by substituting for the item “Ethclorvynol” the item “Ethchlorvynol”;

(vii)

by substituting for the item “Glucose” the item “Glucose unless specified elsewhere in the List”;

(viii)

in the list of “Monoclonal antibody; includes the following:”—

(A)

by inserting after the item “Brodalumab” the item “Brolucizumab”;

(B)

by inserting after the item “Rituximab” the item “Romosozumab”; and

(C)

by inserting after the item “Secukinumab” the item “Siltuximab”;

(ix)

by inserting after the item “Ripasudil” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Risdiplam

All preparations”;

(x)

by deleting the item “Siltuximab” and the particulars relating to it;

P.U. (A) 412 12

(xi)

by inserting after the item “Simvastatin” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Siponimod

All preparations”;

(xii)

by inserting after the item “Succinylated gelatin” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Sucroferric oxyhydroxide

All preparations”;

(xiii)

by inserting after the item “Terconazole” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Teriflunomide

All preparations”; and

P.U. (A) 412 13

(xiv)

by inserting after the item “Tipepidine hybenzate” and the particulars relating to it the following item and particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Tipiracil

All preparations”; and

(b)

in the Appendix to the Poisons List—

(i)

in the list of “Analgesics including antipyretic and anti-inflammatory agents:”, by inserting before the item

“Acetanilide; alkylacetanilides” the item “Aceclofenac”;

(ii)

in the list of “Antihypertensives:”, by inserting after the item “Cilazapril” the item “Cilnidipine”;

(iii)

in the list of “Antineoplastic agents and Immunosuppressants:”—

(A)

by inserting after the item “Rituximab” the item “Romosozumab”;

(B)

by inserting after the item “Simeprevir” the item “Siponimod”; and

(C)

by inserting after the item “Temsirolimus” the item “Teriflunomide”;

P.U. (A) 412 14

(iv)

in the list of “Hypnotics and sedatives:”, by substituting for the item “Ethclorvynol” the item “Ethchlorvynol”; and

(v)

in the list of “Miscellaneous:”—

(A)

by inserting after the item “Brinzolamide” the item “Brolucizumab”;

(B)

by inserting after the item “Dutasteride” the item “Edaravone”;

(C)

by substituting for the item “Glucose” the item “Glucose unless specified elsewhere in the List”;

(D)

by inserting after the item “Ripasudil” the item “Risdiplam”;

(E)

by inserting after the item “Succinylated gelatin” the item “Sucroferric oxyhydroxide”; and

(F)

by inserting after the item “Tiludronic acid; its salts” the item “Tipiracil”.

Made 15 October 2021

[KKM.R.600-1/1/56; PN(PU2)172/XIX]

KHAIRY JAMALUDDIN ABU BAKAR

Minister of Health

Common questions

What is Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021?: Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 is Malaysia P.U. (A), cited as P.U. (A) 412 2021, currently marked in force and first recorded in 2021.
Is Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 still in force?: Yes — Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 is currently in force.
When did Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 take effect?: Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 was first recorded in 2021.
How many sections does Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 have?: Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 contains 2 sections.
Where can I read the official version of Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021?: The official text of Perintah Racun (Pindaan Senarai Racun) (No. 2) 2021 is published at lom.agc.gov.my.

Something wrong on this page?

If one provision's text doesn't match the official source, use Suggest a fix beside that provision — it opens an editor next to the source document. For anything else — a missing amendment, a broken link, out-of-date content, or a removal request — report it here.

Report an issue Request removal